Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 310

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Scorletti, Eleonora, Bhatia, Lokpal, McCormick, Keith G., Clough, Geraldine F., Nash, Kathryn, Hodson, Leanne, Moyses, Helen E., Calder, Philip C., Byrne, Christopher D., Sheron, Nick, Wright, Mark, Curzen, Nick, Rakhit, Dhrubo, Peebles, Charles, Darekar, Angela, Fletcher, Alison, Bateman, Adrian, Williams, Elizabeth, Aspinall, Richard, Fowell, Andrew, Richardson, Tristan, Li Voon Chong, J. S.W., Al-Mrayat, Maén·2014·Hepatology
DOI 10.1002/hep.27289
Open this paper in CoChat — free account

Abstract

There is no licensed treatment for nonalcoholic fatty liver disease (NAFLD), a condition that increases risk of chronic liver disease, type 2 diabetes, and cardiovascular disease. We tested whether 15–18 months of treatment with docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA; Omacor/Lovaza, 4 g/day) decreased liver fat and improved two histologically validated liver fibrosis biomarker scores (primary outcomes). Patients with NAFLD were randomized in a double-blind, placebo-controlled trial (DHA+EPA, n = 51; placebo, n = 52). We quantified liver fat percentage by magnetic resonance spectroscopy in three liver zones. We measured liver fibrosis using two validated scores. We tested adherence to the intervention (Omacor group) and contamination (with DHA and EPA; placebo group) by measuring erythrocyte percentage DHA and EPA enrichment (gas chromatography). We undertook multivariable linear regression to test effects of (1) DHA+EPA treatment (intention-to-treat analyses) and (2) erythrocyte DHA and EPA enrichment (secondary analysis). Median (interquartile range) baseline and end-of-study liver fat percentage were 21.7 (19.3) and 19.7 (18.0) (placebo) and 23.0 (36.2) and 16.3 (22.0) (DHA+EPA). In the fully adjusted regression model, there was a trend toward improvement in liver fat percentage with DHA+EPA treatment (β = −3.64; 95% confidence interval [CI]: −8.0, 0.8; P = 0.1), but there was evidence of contamination in the placebo group and variable adherence to the intervention in the Omacor group. Further regression analysis showed that DHA enrichment was independently associated with a decrease in liver fat percentage (for each 1% enrichment: β = −1.70; 95% CI: −2.9, −0.5; P = 0.007). No improvement in fibrosis scores occurred. Conclusion: Erythrocyte DHA enrichment with DHA+EPA treatment is linearly associated with decreased liver fat percentage. Substantial decreases in liver fat percentage can be achieved with high-percentage erythrocyte DHA enrichment in NAFLD. (Hepatology 2014;60:1211–1221)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.27289

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 32

  1. Bhatia, 2012, Nonalcoholic fatty liver disease: a new and important cardiovascular risk factor?, Eur Heart J, 33, 1190, 10.1093/eurheartj/ehr453 · DOI · Paper page
  2. Targher, 2013, Clinical Review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications., J Clin Endocrinol Metab, 98, 483, 10.1210/jc.2012-3093 · DOI · Paper page
  3. Argo, 2009, Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis., J Hepatol, 51, 371, 10.1016/j.jhep.2009.03.019 · DOI · Paper page
  4. Chalasani, 2012, The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology., Gastroenterology, 142, 1592, 10.1053/j.gastro.2012.04.001 · DOI · Paper page
  5. Levene, 2012, The epidemiology, pathogenesis and histopathology of fatty liver disease., Histopathology, 61, 141, 10.1111/j.1365-2559.2011.04145.x · DOI
  6. Bellentani, 2008, Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach., Hepatology, 47, 746, 10.1002/hep.22009 · DOI
  7. St George, 2009, Independent effects of physical activity in patients with nonalcoholic fatty liver disease., Hepatology, 50, 68, 10.1002/hep.22940 · DOI · Paper page
  8. Huang, 2005, Oneyear intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study., Am J Gastroenterol, 100, 1072, 10.1111/j.1572-0241.2005.41334.x · DOI · Paper page
  9. Ratziu, 2008, Rosiglitazone for nonalcoholic steatohepatitis: oneyear results of the randomized placebocontrolled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial., Gastroenterology, 135, 100, 10.1053/j.gastro.2008.03.078 · DOI · Paper page
  10. Ratziu, 2010, Longterm efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial., Hepatology, 51, 445, 10.1002/hep.23270 · DOI · Paper page
  11. Murphy, 2007, Effects of thiazolidinediones on bone loss and fracture., Ann Pharmacother, 41, 2014, 10.1345/aph.1K286 · DOI
  12. Dietrich, 2009, Vitamin E supplement use and the incidence of cardiovascular disease and allcause mortality in the Framingham Heart Study: does the underlying health status play a role?, Atherosclerosis, 205, 549, 10.1016/j.atherosclerosis.2008.12.019 · DOI
  13. Scorletti, 2013, Omega3 Fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease., Annu Rev Nutr, 33, 231, 10.1146/annurev-nutr-071812-161230 · DOI · Paper page
  14. KrisEtherton, 2003, Omega3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association., Arterioscler Thromb Vasc Biol, 23, 151, 10.1161/01.ATV.0000057393.97337.AE · DOI · Paper page
  15. Parker, 2012, Omega3 supplementation and nonalcoholic fatty liver disease: a systematic review and metaanalysis., J Hepatol, 56, 944, 10.1016/j.jhep.2011.08.018 · DOI · Paper page
  16. Scorletti, 2014, Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega3 fatty treatment in nonalcoholic fatty liver disease., Contemp Clin Trials, 37, 301, 10.1016/j.cct.2014.02.002 · DOI
  17. Guha, 2008, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers., Hepatology, 47, 455, 10.1002/hep.21984 · DOI · Paper page
  18. Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD., Hepatology, 45, 846, 10.1002/hep.21496 · DOI · Paper page
  19. Alberti, 2009, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity., Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 · DOI · Paper page
  20. Duffy, 1995, Alcohol consumption and allcause mortality., Int J Epidemiol, 24, 100, 10.1093/ije/24.1.100 · DOI
  21. Cusi, 2014, Limited value of plasma cytokeratin18 as a biomarker for NASH and fibrosis in patients with nonalcoholic fatty liver disease., J Hepatol, 60, 167, 10.1016/j.jhep.2013.07.042 · DOI · Paper page
  22. Robinson, 2009, Current patterns of diet in communitydwelling older men and women: results from the Hertfordshire Cohort Study., Age Ageing, 38, 594, 10.1093/ageing/afp121 · DOI
  23. Browning, 2012, Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish., Am J Clin Nutr, 96, 748, 10.3945/ajcn.112.041343 · DOI · Paper page
  24. Scorletti, 2014, Corrigendum to design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega3 fatty treatment in nonalcoholic fatty liver disease., Contemp Clin Trials, 38, 156, 10.1016/j.cct.2014.04.004 · DOI
  25. Slee, 2010, Low dietary fishoil threshold for myocardial membrane n3 PUFA enrichment independent of n6 PUFA intake in rats., J Lipid Res, 51, 1841, 10.1194/jlr.M004069 · DOI
  26. Harris, 2004, The Omega3 Index: a new risk factor for death from coronary heart disease?, Prev Med, 39, 212, 10.1016/j.ypmed.2004.02.030 · DOI · Paper page
  27. Nobili, 2014, Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease., PLoS One, 9, e88005, 10.1371/journal.pone.0088005 · DOI
  28. Capanni, 2006, Prolonged n3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with nonalcoholic fatty liver disease: a pilot study., Aliment Pharmacol Ther, 23, 1143, 10.1111/j.1365-2036.2006.02885.x · DOI · Paper page
  29. Zhu, 2008, Effects of n3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia., World J Gastroenterol, 14, 6395, 10.3748/wjg.14.6395 · DOI
  30. Spadaro, 2008, Effects of n3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease., Dig Liver Dis, 40, 194, 10.1016/j.dld.2007.10.003 · DOI · Paper page
  31. Szczepaniak, 2005, Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population., Am J Physiol Endocrinol Metab, 288, E462E468, 10.1152/ajpendo.00064.2004 · DOI · Paper page
  32. Machann, 2006, Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fatselective MRI and volumelocalized 1HMR spectroscopy., Magn Reson Med, 55, 913, 10.1002/mrm.20825 · DOI · Paper page

Cited by

See all 310

Metadata

Authors
Scorletti, E., Bhatia, L., McCormick, K. G., Clough, G. F., Nash, K., Hodson, L., Moyses, H. E., Calder, P. C., Byrne, C. D., Sheron, N., Wright, M., Curzen, N., Rakhit, D., Peebles, C., Darekar, A., Fletcher, A., Bateman, A., Williams, E., Aspinall, R., Fowell, A., Richardson, T., Li Voon Chong, J. S. W., & Al-Mrayat, M.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2014-10
Volume
60
Issue
4
Pages
1211-1221
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.27289
OpenAlex
W2018152768
Cited by
310
References
2
FWCI
30.42
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 335 d)
Funders
National Institute for Health Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.